Congress passed legislation extending rare pediatric disease drug vouchers and expanding FDA authority to mandate cancer studies for children. The package also secures $1.2 billion for Medicare improvements, signaling a major push for specialized medical research and funding.
Congress Passes Bill to Boost Pediatric Cancer Research and Extend Rare Disease Incentives
Congress expands FDA power to require pediatric cancer drug studies; extends rare pediatric drug voucher to 2030
Congress aims to expand FDA-required pediatric cancer drug studies and extend rare disease review vouchers
Analysis generated by AI. Always verify with official sources.